Saladax enters into master collaboration agreement with Bristol- Myers Squibb

BETHLEHEM, Pa.—Saladax Biomedical Inc., aprivately held company developing and commercializing novel diagnostic assaysto achieve the promise of personalized medicine for new and existingtherapeutics, recently the company has expanded its existing relationship withBristol-Myers Squibb Co. by entering into a master early developmentcollaboration agreement, which may include multiple feasibility studies andcompanion diagnostic development projects. With the signing of this agreement,the companies have already initiated a new companion diagnostic project in anundisclosed field. Terms of the agreement were not disclosed.

"Saladax is delighted to continue workingwith Bristol-Myers Squibb to deliver on the promise of personalizedmedicine," said Kevin M. Harter, president and CEO of Saladax."Building on our previous work together, which resulted in clinicallyvaluable Alzheimer's disease assays, we're eager to continue marrying thescientific and clinical knowledge of Bristol-Myers Squibb and Saladax toimprove the lives of patients in other clinical areas."

Saladax and Bristol-Myers Squibb originallyentered into a collaboration in 2010 for the development of clinical diagnostictests for Alzheimer's disease to be used in conjunction with the development ofcertain therapeutic compounds in the Bristol-Myers Squibb pipeline.

SOURCE: Saladax news release

Sponsored

Image Alt Text A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.

How to become a PCR pro

From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.

Ebooks

Tackling mycoplasma contamination in biotherapeutic production

DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.

Webinars

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.

Computational approaches to drug design

Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.

Compendium

Saladax enters into master collaboration agreement with Bristol- Myers Squibb

About the Author

Jeffrey Bouley

Related Topics

Subscribe to our eNewsletters

Sponsored

June 2025